Synopsis of the 6th walker's cay colloquium on cancer vaccines and immunotherapy

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Kast, W Martin ^a   Levitsky, Hyam ^b   Marincola, Francesco M ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROVENGE; TELOMERASE; THERATOPE; TOLL LIKE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL DEATH; CLINICAL TRIAL; CULTURAL FACTOR; CYTOTOXIC T LYMPHOCYTE; DRUG INDUSTRY; DRUG RESEARCH; GENE TARGETING; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION;

EID: 4344616068     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-20     Document Type: Article

References (31)

1. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, et al.: CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004, 109:259-264.
2. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, et al.: Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002, 85:101-144.
3. Vertuani S, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, et al.: Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 2004, 172:3501-3508.
4. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K: Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A 1987, 84:3405-3409.
5. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004, 10:828-839.
6. Sakai JA, Nagai M, Brennan MB, Mora CA, Jacobson S: In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells. Blood 2001, 98:1506-1511.
7. Lewis JD, Reilly BD, Bright RK: Tumor-associated antigens: from discovery to immunity. Int Rev Immunol 2003, 22:81-112.
8. Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF: Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004, 10:76-83.
9. Oosten LE, Blokland E, Van Halteren AG, Curtsinger J, Mescher MF, Falkenburg JH, et al.: Artificial antigen presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 2004, 104:224-226.
10. Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, et al.: Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004, 172:2845-2852.
11. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, et al.: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004, 22:520-527.
12. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, et al.: Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN. J Exp Med 2004, 199:775-784.
13. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003, 9:562-567.
14. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP: CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
15. Spiotto MT, Rowley DA, Schreiber H: Bystander elimination of antigen loss variants in established tumors. Nat Med 2004, 10:294-298.
16. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, et al.: A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19:425-436.
17. Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
18. Hu HM, Poehlein CH, Urba WJ, Fox BA: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002, 62:3914-3919.
19. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003, 33:2123-2132.
20. Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI: CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 2003, 170:2582-2589.
21. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3:35-45.
22. Rini BI: Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002, 4:76-79.
23. Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, et al.: Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 2003, 9:4347-4355.
24. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:326-331.
25. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003, 21:624-630.
26. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, et al.: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002, 3:RESEARCH0035.
27. Jin P, Wang E: Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J Transl Med 2003, 1:8.
28. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol 2003, 24:335-342.
29. Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, et al.: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004, in press.
30. Marincola FM: Translational medicine: a two way road. J Transl Med 2003, 1:1.
31. Mankoff SP, Brander C, Ferrone S, Marincola FM: Lost in translation: obstacles to Translational Medicine. J Transl Med 2004, 2:14